Form D · Biotechnology

RHEOS MEDICINES, INC.

Cambridge, MA · CIK 0001735905

Offering snapshot reported Nov 8, 2018 · SEC filing

Reported sold
$27.5M
Indefinite offering
Investors reported
1
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Mar 20, 2018
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$13.8M$27.5MApr 5, 2018: $15,500,000.00Apr 5, 2018Oct 5, 2018: $21,000,000.00Nov 8, 2018: $27,500,000.00Nov 8, 2018

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$21,000,000 → $27,500,000

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Nov 8, 2018Amendment$27,500,000$6,500,000vs Oct 5, 20181SEC filing
Oct 5, 2018Amendment$21,000,000$5,500,000vs Apr 5, 20181SEC filing
Apr 5, 2018Initial$15,500,000No comparison1SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-309382

Source: Form D, filed Nov 8, 2018. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Jeffrey Bluestone Director
Abbie Celniker Director
Ryan Cohlhepp Executive
J. Duncan Higgons Director
Sanjay Keswani Director, Executive
Dan Matloff Executive
Cary Pfeffer Director
Stephen Sherwin Director
Gad Soffer Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
38 Sidney Street Suite 200
Cambridge, MA, 02139